Teva Pharmaceuticals announces appointment of Dr. Arie Belldegrun to Board of Directors

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced today that Dr. Arie Belldegrun was appointed by the Board of Directors of Teva, at its meeting of February 5, 2013, to fill a vacancy on the Board effective immediately. Dr. Belldegrun’s term of office will extend until Teva’s 2013 Annual Meeting of Shareholders.

“We are pleased to welcome Dr. Belldegrun to our Board. Arie’s extensive experience in the pharmaceutical industry both as a doctor, a business leader and an academic will enable him to make significant contributions to the Board immediately and help guide us as we look for new and innovative ways to bring medicines to patients around the world and continue to increase value for our shareholders,” stated Dr. Phillip Frost, Chairman of the Board, Teva Pharmaceutical Industries Ltd.

Dr. Belldegrun is a director of the UCLA Institute of Urologic Oncology and Professor and Chair of Urologic Oncology at the David Geffen School of Medicine at the University of California, Los Angeles. Dr. Belldegrun serves as the Chairman of the Board of Kite Pharma, Inc., Arno Therapeutics Inc., and TheraCoat, Ltd.

Dr. Belldegrun received his medical degree at the Hadassah Medical School of the Hebrew University and conducted his post-doctoral studies at the Weizmann Institute of Science in Israel. He completed his residency in urologic surgery at Harvard Medical School and his surgical oncology fellowship at the National Cancer Institute (NCI) / National Institute of Health (NIH).